ArticleFrontiers in pharmacology2017
Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- An Asymptomatic, Ectopic Mass as a Presentation of Adrenocortical Carcinoma Due to a Novel GermlineChildren (Basel, Switzerland) · 2023Article
- Approaches to Minimise the Neurodevelopmental Impact of Choroid Plexus Carcinoma and Its Treatment.Life (Basel, Switzerland) · 2023Review
- Molecular heterogeneity of pediatric choroid plexus carcinomas determines the distinctions in clinical course and prognosis.Neuro-oncology · 2023Article
- Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Leptomeningeal dissemination in pediatric brain tumors.Neoplasia (New York, N.Y.) · 2023Article
- Genomic profile of two Brazilian choroid plexus tumors by whole-exome sequencing.Cold Spring Harbor molecular case studies · 2023Article
- Choroid plexus carcinoma in two siblings, with a novel genetic mutation in TP53 - A case report and review of literature.Surgical neurology international · 2022Article
- Aggresomes predict poor outcomes and implicate proteostasis in the pathogenesis of pediatric choroid plexus tumors.Journal of neuro-oncology · 2021Article
- Review
- "Hard" Drug Repurposing for Precision Oncology: The Missing Link?Frontiers in pharmacology · 2018Article
- RareNPJ genomic medicine · 2018Article
- Marrow-ablative consolidation chemotherapy and molecular targeted therapy delivered in a risk-adapted manner for newly diagnosed children with choroid plexus carcinoma:Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroid plexus carcinomas (CPCs) are rare, aggressive pediatric brain tumors with no established curative therapy for relapsed disease, and poor survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.